Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132637 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
NCT02132637 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 68 participants.
The verdict
NCT02132637, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes. Participants will be treated with study insulin daily, in two 4-week study periods. Each participant will receive insulin peglispro during one treatment period and insulin glargine during the other treatment period.
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Peglispro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132637
The ClinicalTrials.gov registry entry for NCT02132637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT02132637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02132637 about?
NCT02132637 is a clinical study titled "A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes". The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes. Participants will be treated with study insulin daily, in two 4-week study periods. Each participant w...
What is the current status of trial NCT02132637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2014-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02132637?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Peglispro (DRUG).
Who is sponsoring clinical trial NCT02132637?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.